Galapagos announces R&D update on 28 February 2008

Mechelen, Belgium; 21 January 2008 – Galapagos NV (Euronext & LSE: GLPG) invites analysts, investors and media to attend an R&D update meeting.  The meeting will take place at BioFocus DPI, a Galapagos company, Darwinweg 24, 2333 CR Leiden, The Netherlands at 14.00 CET (8:00 AM US Eastern time) on 28 February 2008.
Galapagos will present a comprehensive update on its R&D progress, including the newest data on its product programs.  Analysts, investors and journalists who wish to attend the meeting should confirm their attendance via email to by 15 February 2008.
Galapagos also plans a live audio webcast of this update.  To participate in the meeting remotely by telephone, dial +32 2290 1608 prior to 13.55 CET (7:55 AM US Eastern time).  The live audio webcast of the press conference can be accessed on the Galapagos website at
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia.  Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds.  Galapagos currently employs 460 people and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos and BioFocus DPI can be found at and
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.